As research on the unique effects of space environment, especially microgravity and cosmic radiation, on the cardiovascular system is being conducted, research on the development of cardiovascular therapeutics using the space environment is attracting attention. This review comprehensively analyzes the current status and prospects of cardiovascular therapeutics development research utilizing space environment.Microgravity environment has been shown to have a positive effect on the proliferation and differentiation of cardiac progenitor cells and induced pluripotent stem cell-derived cardio myocytes. Cardiac tissue culture and organoid technology have enabled more effective drug screening and disease modeling than on the ground, and changes in gene expression such as Aquaporin-4 have been found to play an important role in cardiac function. Cosmic radiation can cause myocardial remodeling, fibrosis, and vascular endothelial dysfunction, and the underlying mechanisms of these effects include increased oxidative stress, promotion of inflammatory responses, deoxyribo nucleic acid damage, and cell death. Currently, the development of drugs that can prevent or treat cardiovascular damage caused by the space environment is in the early stages, and future research is expected to focus on developing personalized treatments and exploring the potential applications of space medicine research results to terrestrial medicine.

As research on the unique effects of space environment, especially microgravity and cosmic radiation, on the cardiovascular system is being conducted, research on the development of cardiovascular therapeutics using the space environment is attracting attention. This review comprehensively analyzes the current status and prospects of cardiovascular therapeutics development research utilizing space environment.Microgravity environment has been shown to have a positive effect on the proliferation and differentiation of cardiac progenitor cells and induced pluripotent stem cell-derived cardio myocytes. Cardiac tissue culture and organoid technology have enabled more effective drug screening and disease modeling than on the ground, and changes in gene expression such as Aquaporin-4 have been found to play an important role in cardiac function. Cosmic radiation can cause myocardial remodeling, fibrosis, and vascular endothelial dysfunction, and the underlying mechanisms of these effects include increased oxidative stress, promotion of inflammatory responses, deoxyribo nucleic acid damage, and cell death. Currently, the development of drugs that can prevent or treat cardiovascular damage caused by the space environment is in the early stages, and future research is expected to focus on developing personalized treatments and exploring the potential applications of space medicine research results to terrestrial medicine.

As research on the unique effects of space environment, especially microgravity and cosmic radiation, on the cardiovascular system is being conducted, research on the development of cardiovascular therapeutics using the space environment is attracting attention. This review comprehensively analyzes the current status and prospects of cardiovascular therapeutics development research utilizing space environment.Microgravity environment has been shown to have a positive effect on the proliferation and differentiation of cardiac progenitor cells and induced pluripotent stem cell-derived cardio myocytes. Cardiac tissue culture and organoid technology have enabled more effective drug screening and disease modeling than on the ground, and changes in gene expression such as Aquaporin-4 have been found to play an important role in cardiac function. Cosmic radiation can cause myocardial remodeling, fibrosis, and vascular endothelial dysfunction, and the underlying mechanisms of these effects include increased oxidative stress, promotion of inflammatory responses, deoxyribo nucleic acid damage, and cell death. Currently, the development of drugs that can prevent or treat cardiovascular damage caused by the space environment is in the early stages, and future research is expected to focus on developing personalized treatments and exploring the potential applications of space medicine research results to terrestrial medicine.

As research on the unique effects of space environment, especially microgravity and cosmic radiation, on the cardiovascular system is being conducted, research on the development of cardiovascular therapeutics using the space environment is attracting attention. This review comprehensively analyzes the current status and prospects of cardiovascular therapeutics development research utilizing space environment.Microgravity environment has been shown to have a positive effect on the proliferation and differentiation of cardiac progenitor cells and induced pluripotent stem cell-derived cardio myocytes. Cardiac tissue culture and organoid technology have enabled more effective drug screening and disease modeling than on the ground, and changes in gene expression such as Aquaporin-4 have been found to play an important role in cardiac function. Cosmic radiation can cause myocardial remodeling, fibrosis, and vascular endothelial dysfunction, and the underlying mechanisms of these effects include increased oxidative stress, promotion of inflammatory responses, deoxyribo nucleic acid damage, and cell death. Currently, the development of drugs that can prevent or treat cardiovascular damage caused by the space environment is in the early stages, and future research is expected to focus on developing personalized treatments and exploring the potential applications of space medicine research results to terrestrial medicine.

As research on the unique effects of space environment, especially microgravity and cosmic radiation, on the cardiovascular system is being conducted, research on the development of cardiovascular therapeutics using the space environment is attracting attention. This review comprehensively analyzes the current status and prospects of cardiovascular therapeutics development research utilizing space environment.Microgravity environment has been shown to have a positive effect on the proliferation and differentiation of cardiac progenitor cells and induced pluripotent stem cell-derived cardio myocytes. Cardiac tissue culture and organoid technology have enabled more effective drug screening and disease modeling than on the ground, and changes in gene expression such as Aquaporin-4 have been found to play an important role in cardiac function. Cosmic radiation can cause myocardial remodeling, fibrosis, and vascular endothelial dysfunction, and the underlying mechanisms of these effects include increased oxidative stress, promotion of inflammatory responses, deoxyribo nucleic acid damage, and cell death. Currently, the development of drugs that can prevent or treat cardiovascular damage caused by the space environment is in the early stages, and future research is expected to focus on developing personalized treatments and exploring the potential applications of space medicine research results to terrestrial medicine.

The global prevalence of childhood and adolescent obesity, exacerbated by the coronavirus disease 2019 pandemic, affects school-aged children and preschoolers. Early-onset obesity, which carries a high risk of metabolic complications, may contribute to a lower age at the onset of cardiovascular disease. As metabolic diseases such as diabetes, dyslipidemia, and nonalcoholic fatty liver disease observed in adulthood are increasingly recognized in the pediatric population, there is an emphasis on moving disease susceptibility assessments from adulthood to childhood to enable early detection. However, consensus is lacking regarding the definition of metabolic diseases in children. In response, various indicators such as the pediatric simple metabolic syndrome score, continuous metabolic syndrome score, single-point insulin sensitivity estimator, and fatty liver index have been proposed in several studies. These indicators may aid the early detection of metabolic complications associated with pediatric obesity, although further validation studies are needed. Obesity assessments are shifting in perspective from visual obesity to metabolic health and body composition considerations to fill the gap in health impact assessments. Sarcopenic obesity, defined as the muscle- to-fat ratio, has been proposed in pediatric populations and is associated with metabolic health in children and adolescents. The National Health Screening Program for Children in Korea has expanded but still faces limitations in laboratory testing. These tests facilitate timely intervention by identifying groups at a high risk of metabolic complications. Early detection and intervention through comprehensive health screening are critical for mitigating long-term complications of childhood obesity.

The global prevalence of childhood and adolescent obesity, exacerbated by the coronavirus disease 2019 pandemic, affects school-aged children and preschoolers. Early-onset obesity, which carries a high risk of metabolic complications, may contribute to a lower age at the onset of cardiovascular disease. As metabolic diseases such as diabetes, dyslipidemia, and nonalcoholic fatty liver disease observed in adulthood are increasingly recognized in the pediatric population, there is an emphasis on moving disease susceptibility assessments from adulthood to childhood to enable early detection. However, consensus is lacking regarding the definition of metabolic diseases in children. In response, various indicators such as the pediatric simple metabolic syndrome score, continuous metabolic syndrome score, single-point insulin sensitivity estimator, and fatty liver index have been proposed in several studies. These indicators may aid the early detection of metabolic complications associated with pediatric obesity, although further validation studies are needed. Obesity assessments are shifting in perspective from visual obesity to metabolic health and body composition considerations to fill the gap in health impact assessments. Sarcopenic obesity, defined as the muscle- to-fat ratio, has been proposed in pediatric populations and is associated with metabolic health in children and adolescents. The National Health Screening Program for Children in Korea has expanded but still faces limitations in laboratory testing. These tests facilitate timely intervention by identifying groups at a high risk of metabolic complications. Early detection and intervention through comprehensive health screening are critical for mitigating long-term complications of childhood obesity.

The global prevalence of childhood and adolescent obesity, exacerbated by the coronavirus disease 2019 pandemic, affects school-aged children and preschoolers. Early-onset obesity, which carries a high risk of metabolic complications, may contribute to a lower age at the onset of cardiovascular disease. As metabolic diseases such as diabetes, dyslipidemia, and nonalcoholic fatty liver disease observed in adulthood are increasingly recognized in the pediatric population, there is an emphasis on moving disease susceptibility assessments from adulthood to childhood to enable early detection. However, consensus is lacking regarding the definition of metabolic diseases in children. In response, various indicators such as the pediatric simple metabolic syndrome score, continuous metabolic syndrome score, single-point insulin sensitivity estimator, and fatty liver index have been proposed in several studies. These indicators may aid the early detection of metabolic complications associated with pediatric obesity, although further validation studies are needed. Obesity assessments are shifting in perspective from visual obesity to metabolic health and body composition considerations to fill the gap in health impact assessments. Sarcopenic obesity, defined as the muscle- to-fat ratio, has been proposed in pediatric populations and is associated with metabolic health in children and adolescents. The National Health Screening Program for Children in Korea has expanded but still faces limitations in laboratory testing. These tests facilitate timely intervention by identifying groups at a high risk of metabolic complications. Early detection and intervention through comprehensive health screening are critical for mitigating long-term complications of childhood obesity.

The global prevalence of childhood and adolescent obesity, exacerbated by the coronavirus disease 2019 pandemic, affects school-aged children and preschoolers. Early-onset obesity, which carries a high risk of metabolic complications, may contribute to a lower age at the onset of cardiovascular disease. As metabolic diseases such as diabetes, dyslipidemia, and nonalcoholic fatty liver disease observed in adulthood are increasingly recognized in the pediatric population, there is an emphasis on moving disease susceptibility assessments from adulthood to childhood to enable early detection. However, consensus is lacking regarding the definition of metabolic diseases in children. In response, various indicators such as the pediatric simple metabolic syndrome score, continuous metabolic syndrome score, single-point insulin sensitivity estimator, and fatty liver index have been proposed in several studies. These indicators may aid the early detection of metabolic complications associated with pediatric obesity, although further validation studies are needed. Obesity assessments are shifting in perspective from visual obesity to metabolic health and body composition considerations to fill the gap in health impact assessments. Sarcopenic obesity, defined as the muscle- to-fat ratio, has been proposed in pediatric populations and is associated with metabolic health in children and adolescents. The National Health Screening Program for Children in Korea has expanded but still faces limitations in laboratory testing. These tests facilitate timely intervention by identifying groups at a high risk of metabolic complications. Early detection and intervention through comprehensive health screening are critical for mitigating long-term complications of childhood obesity.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.